IPO registrations (S-1, F-1) · Registrants
Theriva Biologics, Inc.
- SEC CIK
- 894158 · filings on EDGAR ↗
- Former names
- Synthetic Biologics, Inc. (2012–2022); ADEONA PHARMACEUTICALS, INC. (2008–2012); PIPEX PHARMACEUTICALS, INC. (2006–2008); SHEFFIELD PHARMACEUTICALS INC (1997–2006); SHEFFIELD MEDICAL TECHNOLOGIES INC (1996–1997)
- Registration
- Form S-1, first filed 2012-12-13, last 2025-03-21; 4 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2018-10-12; declared effective 2012-12-20
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- NV
- Business address
- 9605 MEDICAL CENTER DRIVE, SUITE 270, Rockville, MD 20850
- EIN
- 13-3808303
- Ticker
- TOVX (NYSE)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Theriva Biologics, Inc. on the corporate pages
On this site
- Business registration: SYNTHETIC BIOLOGICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: THERIVA BIOLOGICS, INC. EXACT (EIN (EXACT))
- Federal award recipient: THERIVA BIOLOGICS, INC Fuzzy (name and state)
- Form D issuer: Theriva Biologics, Inc. EXACT (CIK (EXACT))
- SEC filer: ADEONA PHARMACEUTICALS, INC. EXACT (CIK (EXACT))
Filings 30
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2012-12-13 | S-1 | S-1 (registration) | Synthetic Biologics, Inc. | 0001144204-12-067799 ↗ |
| 2012-12-20 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-12-003607 ↗ |
| 2013-05-06 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-13-001415 ↗ |
| 2013-07-16 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-13-002097 ↗ |
| 2015-04-20 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-15-000930 ↗ |
| 2015-04-20 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-15-000931 ↗ |
| 2015-08-18 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-15-002320 ↗ |
| 2015-08-18 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-15-002321 ↗ |
| 2015-10-15 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-15-002770 ↗ |
| 2018-05-15 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-18-001264 ↗ |
| 2018-08-22 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-18-002172 ↗ |
| 2018-09-18 | S-1 | S-1 (registration) | Synthetic Biologics, Inc. | 0001144204-18-049861 ↗ |
| 2018-10-02 | S-1/A | S-1/A (amendment) | Synthetic Biologics, Inc. | 0001144204-18-052016 ↗ |
| 2018-10-10 | S-1/A | S-1/A (amendment) | Synthetic Biologics, Inc. | 0001144204-18-053149 ↗ |
| 2018-10-10 | S-1/A | S-1/A (amendment) | Synthetic Biologics, Inc. | 0001144204-18-053211 ↗ |
| 2018-10-10 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-18-002587 ↗ |
| 2018-10-12 | 424B4 | 424B4 (final prospectus) | Synthetic Biologics, Inc. | 0001144204-18-053648 ↗ |
| 2021-05-11 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-21-001888 ↗ |
| 2021-11-02 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-21-004157 ↗ |
| 2022-09-14 | EFFECT | EFFECT (declared effective) | Synthetic Biologics, Inc. | 9999999995-22-002712 ↗ |
| 2022-12-08 | EFFECT | EFFECT (declared effective) | Theriva Biologics, Inc. | 9999999995-22-003489 ↗ |
| 2024-09-10 | S-1 | S-1 (registration) | Theriva Biologics, Inc. | 0001104659-24-098640 ↗ |
| 2024-09-23 | S-1/A | S-1/A (amendment) | Theriva Biologics, Inc. | 0001104659-24-101897 ↗ |
| 2024-09-25 | EFFECT | EFFECT (declared effective) | Theriva Biologics, Inc. | 9999999995-24-002960 ↗ |
| 2024-09-25 | EFFECT | EFFECT (declared effective) | Theriva Biologics, Inc. | 9999999995-24-002966 ↗ |
| 2024-12-10 | S-1 | S-1 (registration) | Theriva Biologics, Inc. | 0001104659-24-127275 ↗ |
| 2025-01-21 | S-1/A | S-1/A (amendment) | Theriva Biologics, Inc. | 0001104659-25-004895 ↗ |
| 2025-03-21 | S-1/A | S-1/A (amendment) | Theriva Biologics, Inc. | 0001104659-25-026682 ↗ |
| 2025-05-07 | EFFECT | EFFECT (declared effective) | Theriva Biologics, Inc. | 9999999995-25-001443 ↗ |
| 2025-12-02 | EFFECT | EFFECT (declared effective) | Theriva Biologics, Inc. | 9999999995-25-003480 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| MANION MICHAEL F | Director,Officer,TenPercentOwner | PRES CEO; President | 3 | 2006 | |
| KANZER STEVE H | Director,Officer; Director,Officer,TenPercentOwner; Director,TenPercentOwner; TenPercentOwnerOther | CEO; Chairman; Chief Executive Officer | 17 | 2006–2014 | |
| Stergis Nicholas | Director,Officer; Director,TenPercentOwner | Chief Executive Officer | 2 | 2006–2008 | |
| Bisgaier Charles PhD | Director; Director,Officer | President | 2 | 2006–2007 | |
| Kraws Jeffrey J | Director | 20 | 2006–2026 | ||
| Wolf Jeffrey Alan | Director | 22 | 2006–2026 | ||
| Holman Wayne George | TenPercentOwner | 2 | 2006–2007 | ||
| Ridgeback Capital Investments Ltd. | TenPercentOwner | 2 | 2006–2007 | ||
| Ridgeback Capital Management LLC | TenPercentOwner | 2 | 2006–2007 | ||
| RUDICK A JOSEPH | Director | 2 | 2006–2008 | ||
| DORMAN DANIEL J | Director | 3 | 2007 | ||
| KUO JAMES S | Director; Director,Officer | Chairman, CEO & President | 5 | 2007–2011 | |
| Newsome David A. | Officer | Chief Scientific Officer | 2 | 2007 | |
| Lyon Lyman Max Jr | Director,Officer; Officer | CEO; CEO & President | 4 | 2009 | |
| Riley Jeffrey Scott | Director; Director,Officer | CEO and President; Chief Executive Officer | 12 | 2010–2016 | |
| STACKS NELSON K. | Director | 1 | 2012 | ||
| Ballantyne Charles Evan | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 4 | 2012–2015 | |
| Tarriff Scott | Director; Other | 11 | 2012–2020 | ||
| INTREXON CORP | TenPercentOwner | 5 | 2012–2019 | ||
| KIRK RANDAL J | TenPercentOwner | 5 | 2012–2019 | ||
| SHALLCROSS STEVEN A | Director,Officer; Officer | CEO and CFO; Chief Financial Officer; CHIEF FINANCIAL OFFICER; Interim CEO and CFO | 22 | 2015–2026 | |
| Sliman Joseph A. | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 3 | 2017 | |
| MONAHAN JOHN J | Director | 7 | 2020–2026 | ||
| Tufaro Francis | Officer | Chief Operating Officer | 2 | 2022 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-10-24 | Theriva Biologics, Inc. | Biotechnology | $13,109,494 | $13,109,494 | 10 | 1 |
| 2022-08-04 | Synthetic Biologics, Inc. | Biotechnology | $3,000,000 | $3,000,000 | 1 | 1 |
| 2022-03-21 | Synthetic Biologics, Inc. | Biotechnology | $1,467,502 | $1,467,502 | 4 | 1 |
| 2017-09-13 | Synthetic Biologics, Inc. | Biotechnology | $12,000,000 | $12,000,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.